For the molecular diagnostics company to earn such a big boost in its valuation, sales of its COVID-19 test will need to grow at an ambitious rate.
News & Analysis: Co-Diagnostics, Inc.
It claims its Logix in vitro test is 100% accurate, and investors have bid its stock up in consequence. However, even a 2% rate of false positives could be a huge problem for the test and the stock.
Another COVID-19 test maker's pain appears to be behind Co-Diagnostics stock's gain.
This coronavirus testing company's stock has increased 19 times in 2020.
Demand for its coronavirus diagnostic kits could spike in the months ahead.
The company announced two new markets for its COVID-19 diagnostics tests.
The company's COVID-19 test received a key validation.
These stocks have soared while the overall market tanked. But are they buys?
An overall market rebound and some company-specific news are lighting a fire beneath these stocks.
These three healthcare stocks are surging this morning after another day of bad news regarding the SARS-CoV-2 pandemic.